Intravesical mitomycin C is commonly used in the treatment of bladder cancer immediately after transurethral resection of a tumor to reduce cancer recurrence and progression in non–muscle-invasive bladder cancer (NMIBC). However, lack of compliance is common due to associated complications such as chemical cystitis. Lee et al sought to assess the safety and efficacy of intravesical mitomycin C before transurethral resection of bladder tumors in patients with NMIBC. ...
Advertisement
Advertisement
Latest News
Researchers performed a cost-effectiveness analysis of sunitinib and 6 immunotherapy-TKI/immunotherapy drug combinations.
Intracorporeal DUBC may be a safe and effective alternative to RNU for UTUC, according to a new research.
Dr. Ulaner highlights the line(s) of therapy in which novel RLT-PSMA agents are being developed.
Dr. Ulaner explains the data that led to the FDA approval of 177Lu-PSMA-617 and the safety profile of this drug.
Dr. Ulaner details the current application and capabilities of molecular imaging in prostate cancer.
A recent update on the phase 3 MIRAGE trial determined if MRI or CT-guided stereotactic body radiotherapy is most effective.
Researchers examined the impact of care fragmentation on patients receiving neoadjuvant chemotherapy and radical cystectomy.
Prostate cancer drug abiraterone acetate has recently been developed in an oral suspension form as an alternative to tablets.
Advertisement
Advertisement
Editorial Advisory Board
Catherine H. Marshall, MD, MPHEditor | Assistant Professor of Oncology at the Johns Hopkins University School of Medicine
Jérémie Calais, MD, MScEditor | Director of the Theranostics and Clinical Research Programs at the University of California, Los Angeles
Akhil Abraham Saji, MDAssociate Editor | Urology Resident at New York Medical College/Westchester Medical Center
David Ambinder, MDAssociate Editor | Urology Resident at New York Medical College/Westchester Medical Center
Expert Interviews
GU Oncology Now spoke with Shyam Natarajan to discuss Avenda's iQuest and how AI can be used in the field of cancer care.
Cytoreductive nephrectomy is controversial in the metastatic RCC setting, especially in the age of immunotherapy.
Alexander Kutikov speaks about changes he pioneered in the GU surgical landscape, and the future state of GU oncology care.
Colin Dinney, MD, explains the data that led to FDA approval of Adstiladrin for NMIBC and how it impacts the treatment.
Tomi Jun, MD, shares the clinical actionability and utilization of NGS for prostate cancer in a changing treatment landscape.
Dr. Daniel Tennenbaum interviews Dr. Catherine H. Marshall on trends in managing advanced and metastatic prostate cancer.
Knowledge Hubs
Curated clinical content based on conditions, therapies, and technologies
GU Oncology Now delivers the latest news in clinical trials, conference coverage, and more, highlighting advancements in genitourinary oncology treatments and tech.
Get research and breaking news straight to your inbox.
The Uromigos
Podcasts hosted by Professors Thomas Powles, MD, and Brian Rini, MD
Conference Coverage
Live meeting highlights
Norman E Sharpless, MD, University of North Carolina School of Medicine, will present the keynote session.
Attendees will learn about different ways of managing renal cell carcinoma at all stages from research to practice.
Gerhardt Attard, MD, PhD, FRCP, will kick off the event with a session on advanced prostate cancer.
The event will feature world-class science and new and innovative findings in the study of GU malignancies.
Video Insights
Clinical discussions with experts in the field
